TOKYO, Apr 10, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Shipbuilding Co., Ltd., a part of Mitsubishi Heavy Industries (MHI) Group, has acquired Approval in Principle (AiP)* from Nippon Kaiji Kyokai (ClassNK) for its Onboard Carbon Capture and Storage system (OCCS) developed to capture and store CO2 emitted from ships.The OCCS subject to the AiP captures, liquefies, and stores CO2 after pretreatment of the exhaust gas emitted from ships. It is attracting attention as a solution to promote decarbonization of ships.Mitsubishi Shipbuilding has developed the system by utilizing CO2 capture technologies of MHI, which has a wealth of experience with onshore facilities, as core technology, and combining it with exhaust gas pretreatment, CO2 liquefaction, storage, and handling technologies in order to establish as onboard system. Going forward, Mitsubishi Shipbuilding will accelerate the development of this system to bring it into market.MHI Group is currently pursuing strategic measures to strengthen its business for the energy transition. In conjunction with this initiative, Mitsubishi Shipbuilding is making efforts to contribute to the advancement of the maritime industries in Japan and around the world by utilizing its shipbuilding-based marine engineering technologies in addition to the conventional shipbuilding.Mitsubishi Shipbuilding will actively contribute to the decarbonization of ships continuing their effort to reduce greenhouse gas (GHG) emissions from ships, which faces an increasingly urgent priority around the world.*Approval in Principle (AiP) indicates that a certification body has reviewed the basic design of the subject equipment and confirmed that it meets technical requirements and relevant safety standards.The inspection of the basic design for the OCCS system was conducted in accordance with ClassNK's "Guidelines for Shipboard CO2 Capture and Storage Systems."About MHI Group's CO2 capture technologiesMHI Group has been developing the "KM CDR Process™" (Kansai Mitsubishi Carbon Dioxide Recovery Process) and the "Advanced KM CDR Process™" in collaboration with the Kansai Electric Power Co., Inc. since 1990. As of April 2025, the Company has delivered 18 plants adopting these processes. The "Advanced KM CDR Process™" adopts the "KS-21™" solvent, which incorporates technological improvements over the amine-based "KS-1™" and offers superior regeneration efficiency and lower deterioration than the "KS-1™", and it has been verified to provide excellent energy saving performance, reduce operation costs, and result in low amine emissions.Further information on MHI Group's CO2 capture plants: www.mhi.com/products/engineering/co2plants.htmlAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2025 JCN Newswire via SeaPRwire.com.

HONG KONG, Apr 9, 2025 - (ACN Newswire via SeaPRwire.com) - SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a novel investigational therapy targeting the IL-25 (IL-17E) receptor pathway in moderate to severe atopic dermatitis (AD). SM17 uniquely binds to the co-receptor for IL-25, a key alarmin, and blocks downstream signaling – disrupting the inflammatory cascade driven by IL-25 engagement.SM17 Competitive Advantages:- First AD biologic with dual efficacy --- first and the only AD biologic that could reach both NRS-41 and EASI-752 responder rate over 60%3 simultaneously at end of treatment (EOT), comparing to marketed product.- Faster and deeper itch relief than anti-IL-4/13 agents4--- onset of anti-pruritus effect as early as Week 2 (SM17) vs Week 4~6 (other agents), over 90% of patients achieved NRS-4 (SM17) vs 30~40% of patients (other agents) at EOT.- Safer than JAK inhibitors5 --- No serious adverse events (SAEs) nor drug related Grade 3 or above adverse events (AEs) reported， minimum risk of serious infections or major adverse cardiovascular events (MACE).1 NRS-4: a peak pruritus numeric rating scale (PP-NRS) weekly mean score with a ≥4-point reduction from baseline2 EASI-75: ≥75% reduction from baseline in Eczema Area and Severity Index (EASI) score3 SM17 ph1b NRS-4 responder rate:91.7%, EASI-75 responder rate 75.0%4 Dupixent@ Prescribing information, SOLO-1 & SOLO-2 studies5 RINVOQ@ Prescribing information, Measure Up 1 & Measure Up 2 studiesThis Phase1b study, which evaluated two doses level of SM17 (200mg and 600mg, respectively), met its primary endpoints manifested as the safety profiles in patients with moderate-to-severe AD by demonstrating that SM17 was well-tolerated with no serious adverse event (SAE) or treatment-related adverse events (TRAEs) with grade 3 or above. In terms of efficacy, this study met all the secondary endpoints assessing pruritus, skin healing and AD patients’ quality of life by demonstrating remarkable differences between SM17 treatment groups and placebo group.This study was a 16-week, randomized, placebo-controlled, double-blind study to assess the tolerability, safety and efficacy of SM17 monotherapy in 32 adults with moderate-to-severe AD, most of whom were previously inadequate responder to topical corticosteroids (TCS). Patients with a history of biologic (Dupilumab) or systemic Janus kinase (JAK) inhibitor medication (Upadacitinib) were also enrolled in the study.At week 12, 75.0% of patients（9 /12） in the higher dose group achieved ≥75% reduction from baseline in EASI-75, vs. 0.0% of patients in the placebo group, with difference of responder rate as 75.0%（95% CI：32.00~91.11）. In the lower dose group, 50.0% of patients (6/12) achieved EASI-75, a 50.0% difference vs. placebo (95%CI：9.27~74.62).In the higher dose group, 41.7% of patients (5/12) achieved a validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™) score of 0 (clear) or 1 (almost clear) with a ≥2-point reduction from baseline (vIGA-AD 0/1) at week 12, representing a 41.7% difference vs. placebo (95%CI: 2.28~68.05). In the lower dose group, 25.0% of patients (3/12) achieved this endpoint, a 25.0% difference vs. placebo (95%CI: -11.22~53.23).It is particularly noteworthy that 91.7% of patients (11/12) in the higher dose group achieved a peak pruritus numeric rating scale (PP-NRS) weekly mean score with a ≥4-point reduction from baseline (NRS-4) at week 12, vs. 0.0% of patients in the placebo group. Even in the lower dose group, 66.7% of patients (8/12) achieved this endpoint, remarkably different to that of the placebo group.With regard to the onset of action, SM17 showed obvious anti-pruritus effect as early as week 2 after the initial dose, in either the higher or the lower dose group. The altitude of improvement in pruritus for SM17 treatment groups increased alongside with dosing and reached a mean level of 68% and 57% reduction from baseline in PP-NRS score at week 12, for higher and lower dose groups, respectively, vs. 18% for placebo group. Improvement in pruritus was also maintained for both SM17 treatment groups until week 16, which was 6 weeks away from last dosing (week 10). Improvement in skin healing showed similar trends, with a mean level of 73% and 57% reduction from baseline in EASI score at week 12 for the 2 treatment groups，vs. a mean level of 42% reduction from baseline in placebo group.In addition, this Phase 1b study also met the endpoint of EASI 50 and EASI 90 at week 12, as well as superior improvement comparing to placebo in other skin healing measures as SCORAD and AD body surface area (BSA), or patients’ life quality questionnaire - Dermatology Life Quality Index (DLQI).Major efficacy endpoints results were summarized in the table below.EndpointsSM17 Higher dose (N=12)SM17 Lower dose (N=12)Placebo (N=12)EASI 50(%)Week1283.366.725.0Week1691.758.325.0EASI 75 (%)Week1275.0500.0Week1641.741.70.0EASI 90 (%)Week1241.716.70.0Week1641.741.70.0IGA 0/1 (%)Week1241.725.00.0Week1633.341.70.0NRS-4 (%)Week1291.766.70.0Week1675.058.325.0Safety findings were generally consistent with the safety profile of SM17 previously observed in US Phase 1 and China Phase 1a bridging study. The most frequent TEAEs (≥10%) in SM17 groups were nasopharyngitis and urinary tract infection，with the overall incidence rate difference between the treatment group and the placebo group being less than 5%.Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab, said, "SM17 has the potential to become a first- and best-in-class therapy for atopic dermatitis (AD), a market where a single transformative therapy can achieve multibillion-dollar (US) annual revenue. Pruritus is the primary concern for most of the patients with moderate-to-severe AD，and scratching behavior triggered by itch is likely the key driving factor in recurrent chronic inflammatory cycle in AD. With a favorable safety profile and skin clearance comparable to the most effective existing therapies, SM17 also delivers exceptional efficacy in itch relief – the most critical unmet need for patients. By addressing these key gaps in current treatment options, SM17 is positioned to redefine the standard of care for this debilitating condition. We are accelerating our clinical programs and actively pursuing partnerships to maximize its global impact. Next, we anticipate initiating Phase 2 trials in adults with moderate-to-severe AD. Notably, preclinical studies have shown promising results for SM17 in treating other Type 2 allergic diseases such as asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and idiopathic pulmonary fibrosis (IPF). These findings suggest that SM17 could become a versatile therapeutic for a range of Th2-driven diseases, extending its potential beyond AD as a first- and best-in-class option."About Atopic Dermatitis MarketAtopic dermatitis (AD) is a chronic inflammatory skin disease with a complex pathogenesis involving genetic predisposition, skin barrier dysfunction, immune system dysregulation, and environmental factors. The immunological characteristics of AD are dominated by the Th2 axis, involving mediators such as TSLP, IL-4, IL-13, IL-5, IL-33, IL-31, OX40, and the JAK/STAT signaling pathway. AD typically begins in infancy, with about 50% of patients developing symptoms before the age of one. The disease follows a chronic and relapsing course.Epidemiological studies indicate that there are at least 230 million AD patients worldwide, with China having a substantial patient population exceeding 70 million, of which moderate-to-severe cases account for approximately 28%. In comparison, the U.S. has an estimated 16.5 million adult AD patients, with moderate-to-severe cases making up around 40%.According to Precedence Research, the global AD drug market was value at 13.62 billion in 2023 and is projected to reach 13.62 billion in 2023 and is projected to reach 31.44 billion by 2034. Current treatment options vary in efficacy and include topical medications (e.g., corticosteroids [TCS], calcineurin inhibitors [TCI]), oral antihistamines, and biologics, each with its own advantages and limitations.While conventional therapies like TCS, TCI, and oral antihistamines remain standard treatments, biologics such as dupilumab have significantly improved patients' quality of life. However, limitations such as slow onset, insufficient itch relief, and long-term safety concerns leave many patients' needs unmet. Another drug, the JAK inhibitor upadacitinib, faces safety-related challenges. In 2024, dupilumab's global sales surpassed $14 billion, highlighting the immense potential of the AD market and driving pharmaceutical companies to accelerate the development of differentiated therapies. Currently, competition in the AD field is primarily focused on target innovation: Among the top 10 AD clinical targets in China and globally, seven overlap, with IL-4Rα and JAK1 being the top two. In terms of clinical phases, only 14% of China's AD trials are in Phase 3 or later, compared to 23% globally (excluding Phase 2/3 trials), indicating that China's strategy remains largely fast-follow. Moreover, China's target landscape is more concentrated, with the top three targets (IL-4Rα, JAK1, and PDE4) accounting for 46% of clinical trials, whereas global AD clinical targets are more evenly distributed.About SM17SM17 is a novel, First-in-Class (FIC), humanized, IgG4-κ monoclonal antibody, which is a global first in-class monoclonal antibody drug targeting IL-25 receptor with the potential for treating AD, asthma, idiopathic pulmonary fibrosis and other immunological disorders. SM17 could suppress Type 2 helper T (Th2) immune responses by binding to IL-25 receptor (also known as IL-17RB) on Type 2 Innate Lymphoid cells (ILC2s) and Th2 cells, to block a cascade of responses induced by IL-25 and suppress the release of the downstream Th2 cytokines such as IL-4, IL-9 and IL-13. IL-25 is a critical cytokine classified as ‘‘alarmin’’, which has shown to be implicated in the pathogenesis of autoimmune and inflammatory skin diseases, especially in AD. Current approved therapies for AD, including biologics, can significantly improve eczema area and severity index (EASI) and patient’s quality of life, but they either are slow in response, especially in anti-pruritic effect, or have safety concerns. With the novel mechanism of action, SM17 hopefully will become a new and probably better treatment option for AD, which is fast in anti-pruritic response, effective in skin healing and safe, addressing the unmet medical needs not covered by current treatment modalities.About Differences in Targeting the Receptor (IL-25R) vs the Ligand (IL-25)Using AD as a model, stimulated skin will continuously release IL-25, and neutralizing IL-25 with antibodies does not instantly impart relief. SM17 uniquely blocks one of the IL-25 receptor subunits (IL-17RB) in a non-competitive manner. We have in-house data supporting that SM17 can block receptor signal transduction without affecting IL-25 engagement with the receptor, so SM17 can provide fast anti-pruritic and anti-inflammatory effects arising from IL-25/IL-25 receptor interactions.Additionally, the number of receptors on cell surface is limited, and if sufficient antibodies against the receptor are added and all receptors blocked, therapeutic response will persist regardless of the amount of IL-25 released. This is the case for SM17, which blocks the limited number of receptors on cell surface. Once fully occupied, it stops the signaling regardless of IL-25 levels. This allows a fast, long-lasting inhibition and avoids high-dose requirements.Contrarily, antibodies targeting IL-25 must neutralize the ligand directly, while AD skin continuously releases IL-25 such that anti-IL-25 therapies require high doses to “mop-up” all newly released IL-25. This delays itch and inflammation relief.About SinoMab BioScience LimitedSinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. SinoMab is headquartered in Hong Kong with its R&D base in Hong Kong and production base in mainland China. The Company's flagship product Suciraslimab (SM03) is a potential global first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. SM03 (Suciraslimab) has completed the Phase 3 clinical trial for RA in China and is pending NMPA’s marketing approval for RA in China. In addition, the Company possesses other potential first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren’s syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases with major unmet clinical needs.Media enquiriesStrategic Financial Relations LimitedVeron Ng Tel: +852 2864 4831Phoenix Fung Tel: +852 2114 4939Shannon Lei Tel: +852 2114 2881Will Cheng Tel: +852 2864 4894Email: sprg_sinomab@sprg.com.hk Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Apr 10, 2025 - (JCN Newswire via SeaPRwire.com) - Honda announced that Honda’s NC750X large sport model has been named winner of the Red Dot Design Award(1) Product Design category, and the EM1 e: electric motorcycle won the iF Design Award(2) in the Product Design category. Both awards are one of the most respected design awards in the world, and this is the sixth consecutive year that Honda has received a Red Dot Design Award, and the third time since 1997 that it has received an iF Design Award.About the award-winning Honda productsNC750XThe NC750X crossover model combines the fun of touring with ease of use in everyday situations such as commuting. It has been well received by a wide range of customers for its in-line 2-cylinder 745cc engine with powerful torque characteristics for easy handling and excellent fuel economy, low center of gravity packaging for easy handling, and user-friendly luggage storage.Key design featuresSharp and powerful design and an adventure-style exterior raise the rider’s expectations. Its fairing is made of plant-derived bioplastic and recycled materials, a world-first*3 for motorcycle exterior components, and the elimination of paint reduces CO2 emissions. While reducing environmental impact, it also delivers vibrant colors and exceptional design.EM1 e:Developed with the concept of an “electric scooter ‘just right’ for people,” the EM1 e: is a personal-use, electric scooter that fits in well with customers’ lifestyles and daily lives. The EM1 e: is powered by one unit of the Honda Mobile Power Pack e: swappable battery, realizing clean and quiet riding.Key design featuresThe EM1 e: features simple and slim packaging realized by the optimization of the layout of key components. High-brightness LEDs are adopted for the lights, contributing to greater peace of mind experienced by customers while riding at night. The headlight features a simple, flush-surface design, highlighting the iconic look of EM1 e:.Comments by Toshinobu Minami, Managing Director, Chief Operating Officer, Design Center, Honda R&D Co., Ltd.:“We are very honored to receive the Red Dot Design Award for the sixth consecutive year, and this year, we also received the iF Design Award. We believe that this is the result of people resonating with Honda Design’s passion of ‘designs that enrich the lives of our customers through experiences and products resulting from a human-centric approach’. Honda will continue to create new values that surprise and inspire people, and provide the joy of expanding their life’s potential.” (1) The Red Dot Award was founded in 1955 and has become one of the most respected design awards worldwide. The award is administered by Design Zentrum Nordrhein Westfalen in Essen, Germany. For the Product Design awards, 51 categories of industrial products are judged on 9 criteria including the degree of innovation, functionality, durability and ergonomics.(2) The iF Design Award was established in 1954, and is one of the most respected design awards along with the Red Dot Design Award. The award is administrated by iF International Forum Design, based in Hannover, Germany. The award consists of nine categories: Product Design, Packaging Design, Communication Design, Service Design, Architecture, Interior Architecture, Professional Concept, User Experience (UX), and User Interface (UI).(3) Honda internal research Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Apr 9, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Corporation ("MC") has agreed to participate in a demonstration project ("the Project") for the development of a hydrogen-based fluidized bed fine ore reduction process ("HYFOR") and electric smelting furnace (“Smelter”) as a strategic partner of Primetals Technologies ("Primetals") (Headquarters: UK, steel machinery company), along with Rio Tinto (Headquarters: UK/Australia, mining company) and voestalpine (Headquarters: Austria, steel company).This project entails constructing and operating an industrial-scale prototype plant for a new hydrogen-based ironmaking process at the voestalpine steelworks in Linz, Austria. Operations are scheduled to begin in mid-2027. The new ironmaking process has a projected capacity of 3 tons per hour and will produce hot metal and hot briquetted iron using the HYFOR and Smelter technologies developed by Primetals. Rio Tinto will supply 70 percent of the iron ore for the Project.HYFOR is the world’s first direct reduction technology for iron ore fines that does not require any agglomeration steps and enables the use of a wide variety of iron ores as feedstock. Since 2021, Primetals has operated a pilot plant and has run numerous successful test campaigns. By using hydrogen derived from renewable energy, it can also significantly reduce CO2 emissions compared to existing ironmaking processes. Powered by renewable energy, the Smelter is used for melting and final reduction of direct reduced iron (“DRI”) to produce hot metal for the steelmaking plant. Funding for the investment and operation of this prototype plant has been provided by the Austrian federal government and the European Union.DRI has low CO2 emissions in the ironmaking process and the demand for DRI is expected to increase in the medium to long term. Once HYFOR and Smelter technologies are demonstrated through the Project, they will play an important role in decarbonizing the steel industry. Through the promotion of this project, MC will continue to contribute to the realization of a decarbonized society.About voestalpinevoestalpine is a globally leading steel and technology group with a unique combination of materials and processing expertise. voestalpine, which operates globally, has around 500 Group companies and locations in more than 50 countries on all five continents. The voestalpine Group has been listed on the Vienna Stock Exchange since 1995. With its premium products and system solutions, voestalpine is a leading partner to the automotive and consumer goods industries, as well as to the aerospace and energy industries. The company is also the global market leader in railway systems, tool steel, and special sections. voestalpine is committed to the global climate goals and has a clear plan for transforming steel production with its greentec steel program. In the business year 2023/24, the Group generated revenue of EUR 16.7 billion, with an operating result (EBITDA) of EUR 1.7 billion; it has around 51,600 employees worldwide.About Rio TintoRio Tinto operates in 35 countries where our 60,000 employees are working to find better ways to provide the materials the world needs. Our portfolio includes iron ore, copper, aluminium and a range of other minerals and materials needed for people, communities and nations to grow and prosper, and for the world to cut greenhouse gas emissions to net zero. We have more than 150 years of mining and processing experience guiding our work. We have put climate change at the heart of our strategy, combining investments in commodities that enable the energy transition with actions to decarbonise our operations and value chains.About Primetals TechnologiesPrimetals Technologies, Limited, headquartered in London, United Kingdom, is a pioneer and world leader in the fields of engineering, plant building, and the provision of lifecycle services for the metals industry. The company offers a complete technology, product, and services portfolio that includes integrated electrics and automation, digitalization, and environmental solutions. This covers every step of the iron and steel production chain—from the raw materials to the finished product—and includes the latest rolling solutions for the nonferrous metals sector. Primetals Technologies is a Group Company of Mitsubishi Heavy Industries, with around 7,000 employees worldwide.About Mitsubishi CorporationMitsubishi Corporation is a global integrated business enterprise that develops and operates business together with its offices and subsidiaries worldwide. MC has 8 Business Groups that operate across virtually every industry: Environmental Energy, Material Solution, Mineral Resources, Urban Development and Infrastructure, Mobility, Food Industry, Smart-Life Creation, and Power Solution.Inquiry RecipientMitsubishi CorporationTelephone:+81-3-3210-2171 Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Apr 9, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Environmental & Chemical Engineering Co., Ltd. (MHIEC), a part of Mitsubishi Heavy Industries (MHI) Group, has completed refurbishment of the core facilities of Eco Clean Plaza Miyazaki, a waste-to-energy plant in Miyazaki city in southern part of Kyushu. The refurbishment work, which was ordered in 2021, took place over a four-year span from FY2021 through FY2024. The refurbishment, enabling a waste treatment capacity of 579 tonnes per day (tpd), has extended the plant's service life and achieved reduction in CO2 emissions.Eco Clean Plaza Miyazaki encompasses facilities not only for waste incineration but also recycling and final waste management. It treats waste from Miyazaki city as well as nine nearby localities. The incineration facilities were designed and constructed by MHI and completed in October 2005. They incorporate three stoker type incinerators(Note1) each having a waste treatment capacity of 193 tpd, and related facilities. Power generation capacity using waste heat is 11,200 kW.Under the refurbishment work, upgrades have been made to major equipment superannuated after more than 15 years in operation, to achieve stable combustion and operation over the long term. Replacements include equipment involved in combustion, cooling of combustion gas, waste gas treatment, waste heat utilization, ventilation, and ash removal, as well as electrical instrumentation. Plant service life extension work was carried out adopting MHIEC's proprietary new combustion control system. Stable combustion has been realized with a lower air ratio(Note2) than previously.A CO2 reduction rate of 31.86%(Note3) was attained, significantly higher than the original 17.25% target. Factors contributing to the higher rate include: replacement to a feeder and boiler piping that enable higher durability responding to the low air ratio; increased power generation making efficient use of waste steam, achieved by changing to a low-temperature denitration catalyst; and the compound effects of adopting high-efficiency motors, converting to inverter type equipment, and optimization of plant equipment.The refurbishment work was difficult because it had to be undertaken amid continuing waste treatment, and because it coincided with the spread of the coronavirus pandemic. Nevertheless, work proceeded on schedule thanks to the further strengthening of coordination with all relevant counterparts and meticulous care exercised throughout, enabling the project to be successfully completed on time.MHIEC succeeded MHI's environmental protection business in 2008, taking over its accumulated technological development capabilities in environmental protection systems and abundant expertise in the construction, operation, and maintenance of waste management facilities both in Japan and overseas. Based on this robust track record, the company is well positioned to propose comprehensive solutions encompassing all aspects from plant construction to operation and maintenance. Going forward, the Company will continue proactively proposing solutions for extending the service life of existing waste treatment facilities, coping with global warming, and reducing maintenance, management and other lifecycle costs, to contribute to realization of a carbon neutral society.1A stoker furnace is the main type of waste-to-energy plant. Air is supplied from below a fire grate made of heat-resistant castings to propel the materials to be burned (waste, etc.).2Air ratio is calculated by dividing the real volume of air fed into the incinerator by the theoretical minimal amount of air necessary for waste combustion.3CO2 reduction rate based on the Ministry of the Environment's published material.Overview of Eco Clean Plaza Miyazaki Incineration PlantTreatment capacity579 tonnes per day (193 tpd x 3 units)Treatment methodIncineration (stoker type)Power generation capacity11,200 kWAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2025 JCN Newswire via SeaPRwire.com.